359 related articles for article (PubMed ID: 28493027)
21. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
23. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
Colanta A; Lin O; Tafe L; Ghossein R; Nafa K; Mitchell T; Ladanyi M; Arcila M
Acta Cytol; 2011; 55(6):563-9. PubMed ID: 22156467
[TBL] [Abstract][Full Text] [Related]
25. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
26. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.
Gupta N; Dasyam AK; Carty SE; Nikiforova MN; Ohori NP; Armstrong M; Yip L; LeBeau SO; McCoy KL; Coyne C; Stang MT; Johnson J; Ferris RL; Seethala R; Nikiforov YE; Hodak SP
J Clin Endocrinol Metab; 2013 May; 98(5):E914-22. PubMed ID: 23539734
[TBL] [Abstract][Full Text] [Related]
27. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
28. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract][Full Text] [Related]
29. Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration.
Monaco SE; Pantanowitz L; Khalbuss WE; Benkovich VA; Ozolek J; Nikiforova MN; Simons JP; Nikiforov YE
Cancer Cytopathol; 2012 Oct; 120(5):342-50. PubMed ID: 22605559
[TBL] [Abstract][Full Text] [Related]
30. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
31. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K
Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901
[TBL] [Abstract][Full Text] [Related]
32. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW.
Nikiforov YE
Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687
[TBL] [Abstract][Full Text] [Related]
33. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma.
Zhao L; Dias-Santagata D; Sadow PM; Faquin WC
Cancer Cytopathol; 2017 May; 125(5):323-331. PubMed ID: 28192645
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
[TBL] [Abstract][Full Text] [Related]
35. Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
Song YS; Jung CK; Jung KC; Park YJ; Won JK
J Korean Med Sci; 2017 Oct; 32(10):1721-1726. PubMed ID: 28875621
[TBL] [Abstract][Full Text] [Related]
36. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.
Bongiovanni M; Molinari F; Eszlinger M; Paschke R; Barizzi J; Merlo E; Giovanella L; Fasolini F; Cattaneo F; Ramelli F; Mazzucchelli L; Frattini M
Cytopathology; 2015 Oct; 26(5):288-96. PubMed ID: 25487739
[TBL] [Abstract][Full Text] [Related]
37. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
38. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
[TBL] [Abstract][Full Text] [Related]
39. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract][Full Text] [Related]
40. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]